Edwards Lifesciences Co. (NYSE:EW) is Railway Pension Investments Ltd’s 10th Largest Position

Railway Pension Investments Ltd decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 10.6% in the 1st quarter, Holdings Channel reports. The firm owned 1,695,580 shares of the medical research company’s stock after selling 200,100 shares during the period. Edwards Lifesciences accounts for about 1.6% of Railway Pension Investments Ltd’s investment portfolio, making the stock its 10th biggest holding. Railway Pension Investments Ltd’s holdings in Edwards Lifesciences were worth $162,030,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in Edwards Lifesciences by 4.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock worth $31,603,000 after buying an additional 14,087 shares during the last quarter. Empowered Funds LLC raised its position in Edwards Lifesciences by 151.2% during the 1st quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock worth $1,923,000 after buying an additional 12,112 shares during the last quarter. Telos Capital Management Inc. raised its position in Edwards Lifesciences by 158.2% during the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after buying an additional 56,000 shares during the last quarter. Arlington Trust Co LLC raised its position in Edwards Lifesciences by 5,092.4% during the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after buying an additional 12,069 shares during the last quarter. Finally, HealthInvest Partners AB purchased a new position in Edwards Lifesciences during the 4th quarter worth $1,587,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian acquired 580 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares in the company, valued at approximately $280,198.32. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, VP Daniel J. Lippis sold 857 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $85.60, for a total value of $73,359.20. Following the transaction, the vice president now owns 23,890 shares in the company, valued at $2,044,984. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bernard J. Zovighian purchased 580 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders have sold a total of 30,099 shares of company stock worth $2,680,879 in the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 1.7 %

NYSE:EW traded down $1.03 on Friday, reaching $60.83. The stock had a trading volume of 6,789,806 shares, compared to its average volume of 6,907,783. The company has a market cap of $36.64 billion, a price-to-earnings ratio of 26.20, a P/E/G ratio of 2.57 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The firm’s fifty day moving average is $85.32 and its two-hundred day moving average is $86.41. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.66 EPS. Equities analysts expect that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on EW shares. Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, July 25th. TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $100.00 to $70.00 in a research note on Thursday, July 25th. Daiwa America raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday. Finally, Barclays lowered their price target on shares of Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.